Purpose The α v β 3 integrin represents a potential target for noninvasive imaging of angiogenesis. The purpose of this study was to evaluate a novel one-step labeled integrin α v β 3 -targeting positron emission tomography (PET) probe, 18 F-AlF-NOTA-PRGD2, for angiogenesis imaging in a myocardial infarction/reperfusion (MI/R) animal model. Methods Male Sprague-Dawley rats underwent 45-min transient left coronary artery occlusion followed by reperfusion. The myocardial infarction was confirmed by ECG, 18 F-fluorodeoxyglucose (FDG) imaging, and cardiac ultrasound. In vivo PET imaging was used to determine myocardial uptake of 18 F-AlF-NOTA-PRGD2 at different time points following reperfusion. The control peptide RAD was labeled with a similar procedure and used to confirm the specificity. Ex vivo autoradiographic analysis and CD31/ CD61 double immunofluorescence staining were performed to validate the PET results.
Introduction
After myocardial ischemia/reperfusion (MI/R) injury occurs, new blood vessels form primarily from the ischemic border zone into the infarcted tissue via either angiogenesis or vasculogenesis [1] . The process will restore oxygen and nutrient supply to the infarcted tissue and is considered to be a key factor for post-ischemic repair [2] . Accumulating data support that imaging of post-MI/R angiogenesis may provide additional in vivo insight into the time course, magnitude, heterogeneity, and localization of angiogenesis-related proteins and genes [3] . Integrins are a family of proteins that facilitate cellular adhesion and migration to extracellular matrix proteins found in intercellular spaces and basement membranes, and regulate cellular entry and withdrawal from the cell cycles [4] . Especially α v β 3 integrin has a key role in endothelial cell survival and migration during angiogenesis [5, 6] . α v β 3 integrin is highly expressed on activated neovascular endothelial cells during angiogenesis [6] . In contrast, expression of integrin α v β 3 is low in resting endothelial cells and most normal organ systems [7] . Therefore, integrin α v β 3 is a promising target for angiogenesis imaging with the specific probes including arginine-glycine-aspartic acid (RGD)-containing peptides [8] .
Besides intensive tumor angiogenesis imaging with RGD-based imaging probes [9] , integrin α v β 3 expression in the heart after MI/R injury has been noninvasively investigated by a number of isotopes including 99m Tc, 111 In, and 123 I for single photon emission computed tomography (SPECT) imaging [10] [11] [12] and 18 F for positron emission tomography (PET) imaging [13, 14] . Compared with SPECT, PET offers high sensitivity, reasonable spatial resolution, and permits more accurate attenuation correction.
With almost 100% positron efficiency, low β + energy (0.64 MeV), and relatively short physical half-life (T 1/2 0 109.7 min), 18 F is the most widely used positron-emitting radioisotope for PET imaging, and its physical properties are ideally suited for RGD peptide-based PET imaging probes. The majority of methods used in labeling RGD peptides with 18 F use a prosthetic group, such as N-succinimidyl-4-[ [16] . The time-consuming multiple-step synthetic procedure required for preparation may hinder the widespread use of these 18 F-labeled RGD tracers. Efforts have been made with some success to simplify the labeling procedure by direct labeling of RGD peptides with a pre-attached functional group with a proper leaving group for fluoride displacement [17] . On the other hand, labeling radioactive metal ions through a pre-attached chelator on RGD peptides has been blessed with a much simpler procedure [18] [19] [20] . Application of chelation chemistry has led to recent discovery and development of an 18 F-fluoridealuminum complex to radiolabel peptides, which provides a strategy to simplify the labeling procedure [21] [22] [23] . We also performed a comparison study and found that 18 F-AlF-NOTA-PRGD2 has imaging properties and pharmacokinetics comparable to those of 18 F-FPPRGD2 in tumor xenograft models. Considering the ease of preparation and good imaging qualities, 18 F-AlF-NOTA-PRGD2 is a promising alternative to 18 F-FPPRGD2 for PET imaging of integrin α v β 3 expression [24] .
In this study, we established a rat model of experimental MI/R and performed longitudinal PET imaging using 18 F-AlF-NOTA-PRGD2. With PET imaging, we successfully visualized and quantified neoangiogenesis after MI/R noninvasively.
Materials and methods

General materials
All reagents were of analytical grade and were obtained from commercial sources. 18 The synthesis of 18 F-AlF-NOTA-PRGD2 was performed according to the procedure reported previously [24] . In brief, 3 μl of 2 mM aluminum chloride in 0.2 M pH 4 sodium acetate buffer was added to a 1-ml V-vial containing 0.1 ml of aqueous [ 18 F]fluoride (0.37 GBq) and heated at 100°C for 10 min to form the aluminum-fluoride complex. Then 6 μl of 2 mM NOTA-PRGD2 in 0.2 M pH 4 sodium acetate buffer was added and heated at 100°C for another 10 min. The reaction mixture was directly loaded on the C18 cartridge without HPLC purification and was eluted off with 0.3 ml of 1 mM HCl ethanol solution. The final product was buffered in phosphate-buffered solution (PBS) for in vivo study. 18 F-AlF-NOTA-RAD was synthesized by a similar procedure.
Animal model of coronary occlusion and reperfusion
All animal studies were conducted in accordance with the principles and procedures outlined in the Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee of the Clinical Center, NIH. Adult male Sprague-Dawley rats weighing from 250 to 300 g were used for this study. Anesthesia was induced with 5% isoflurane and maintained with 2% isoflurane. After the animals were intubated for mechanical ventilation, MI/R was induced by ligation of the left anterior descending coronary artery 2-3 mm from the tip of the left auricle with a 6-0 polypropylene suture. Forty-five minutes after the coronary occlusion, the suture was removed to obtain reperfusion. In the sham-operated animals, a suture was placed in the myocardium (without ligating the left coronary artery). The occlusion and reperfusion were confirmed by ST segment elevation on an electrocardiogram monitor (EC-60 model, Silogic) and 18 F-FDG imaging at 2 days after surgery.
Assessment of left ventricular (LV) contractility with echocardiography
Cardiac function was assessed as previously described [25] . Briefly, 7 days after MI/R, the rats received isoflurane (3%) for general anesthesia and were placed on the scanning table. Echocardiographic images were obtained using a dedicated small animal high-resolution imaging unit and a 30-MHz linear transducer (Vevo 770, VisualSonics) [26] . Using the parasternal short-axis view, LV end-diastolic and LV end-systolic diameters (LVEDD and LVESD, respectively) were measured, and LV fractional shortening was calculated as (LVEDD − LVESD)/LVEDD × 100. All measurements were averaged on three consecutive cardiac cycles.
Small animal PET scan At 3 days, 1 week, 3 weeks, and 4 months after MI/R, PET scans were performed using an Inveon microPET scanner (Siemens Preclinical Solutions) [27] . Animals were anesthetized with isoflurane (3%) and approximately 13 MBq (350 μCi) of 18 F-AlF-NOTA-PRGD2 or 18 F-AlF-NOTA-RAD was administered via tail vein injection. Ten-minute static PET images were acquired at 1 h after injection of the tracer. The images were reconstructed using a twodimensional ordered subset expectation maximum (2-D OSEM) algorithm, and no correction was applied for attenuation or scatter. For each scan, regions of interest (ROIs) were drawn using vendor software (ASI Pro 5.2.4.0) on decay-corrected whole-body coronal images. The radioactivity concentrations (accumulation) within the heart were obtained from mean pixel values within the multiple ROI volume and then converted to megabecquerel per milliliter. These values were then divided by the administered activity to obtain (assuming a tissue density of 1 g/ml) an image ROI-derived percent injected dose per gram (%ID/g). In addition, the signal from the infarcted area was compared with the contralateral myocardium (at the septal level), which was taken as background signal, and expressed as the signal to background ratio. To assess the specificity of tracer uptake, 18 mg/kg of cyclic RGD peptide dimer E[c (RGDyK)] 2 was injected 10 min before 18 F-AlF-NOTA-PRGD2 (18.5 MBq) administration in rats at 1 week after MI/R (n03).
Immediately after the 18 F-AlF-NOTA-PRGD2 scan, animals were kept on the scanning gantry (for image coregistration) and injected with 18.5 MBq (500 μCi) of 18 F-FDG. One hour after, 10-min static acquisitions were performed with the mid-thorax in the center of the field of view (FOV), and images were reconstructed and analyzed with the same procedure described above.
Autoradiography
At 3 days, 1 week, 3 weeks, and 4 months after MI/R, in parallel with PET imaging, the same amount of 18 F-AlF-NOTA-RGD2 was administered to rats. At 1 h after the administration, the heart of each rat was excised and then embedded and frozen in CRYO-OCT compound (TissueTek). Serial short-axis sections in 1-mm intervals (15 μm thickness each) covering the entire heart were obtained using a cryostat (UltraPro 5000, Vibratome, St. Louis, MO, USA). The autoradiographic exposure was performed for 12 h and then developed in a Cyclone Plus Storage Phosphor System (PerkinElmer, Shelton, CT, USA). The acquired photos were analyzed with Optiquant Acquisition and Analysis Software V5.0 (PerkinElmer). The ROI was manually defined for a focal myocardial tracer uptake region and a contralateral normal region on a mid-myocardial section. If no focal myocardial tracer accumulation was observed, ROIs were placed over the anterolateral wall. Radioactivity values of each ROI were measured in digital light units (DLU)/per area (mm 2 ). DLU is an arbitrary linear unit that describes the intensity of photon emissions released during the scan. The 18 F-AlF-NOTA-PRGD2 uptake ratio was calculated by dividing the ROI value of the focal tracer uptake region with that of the contralateral normal area.
H&E and TTC staining
Slices with 15 μm thickness adjacent to those used for autoradiography were selected for hematoxylin and eosin (H&E) by use of standard techniques. Two millimeter thick slices adjacent to those used for autoradiography and H&E imaging were also prepared and stained with a buffered solution of 2,3,5-triphenyl-2H-tetrazolium chloride (TTC) at 38°C to identify myocardial infarction.
Immunofluorescence staining
Myocardial frozen tissue slices (5-μm thick) were fixed with ice-cold acetone for 10 min and dried in the air for 30 min. The slices were rinsed with PBS for 2 min and blocked with 10% donkey serum for 30 min at room temperature. For staining of CD31 and CD61, the slices were incubated with mouse anti-rat CD31 (1:20, BD Pharmingen™) and hamster anti-rat CD61 (1:20, BD Pharmingen™) antibody. The slices were incubated with Cy3-conjugated donkey antimouse and DyLight 488-conjugated goat anti-hamster secondary antibody (1:100, Jackson ImmunoResearch Laboratories, Inc.). Fluorescence images were acquired with an epifluorescence microscope (Olympus, X81).
Statistical analysis
Data are expressed as mean±SD. Statistical analysis used the unpaired Student's t test with unequal variance (for comparison between sham-operated and MI animals) and the paired Student's t test for comparison before and after MI. A p value<0.05 was considered statistically significant.
Results
Chemistry and radiochemistry
The structure of 18 F-AlF-NOTA-PPRGD2 is shown in Fig. 1a . The labeling efficiency for 18 F-AlF-NOTA-PPRGD2 varied between 5 and 25% depending on the reaction volumes. When the reaction volume was kept between 50 and 100 μl, the yield was consistently between 20 and 25%. The total synthesis time was about 25 min without HPLC purification. The radiochemical purity was over 97% (Fig. 1b) .
Characterization of MI/R model
The MI/R procedure had a mortality of 15-20%, similar to that reported by other investigators [25] . The success of the MI/R model was confirmed by ST-T segment elevation using ECG during surgery (Fig. 2a) . There was no difference in weight or heart rate between sham (n03) and MI/R (n08) animals (data not shown). Three days after surgery, an obvious uptake defect of 18 F-FDG in the anterolateral wall of the left ventricle was observed with 18 F-FDG PET (Fig. 2b) . On day 7 after MI/R, akinesis of the anterolateral wall with a significant decrease in cardiac function was identified by M-mode high-resolution ultrasound (Fig. 2c) Due to the high metabolic rate of myocardium, heart is one of the major organs for 18 F-FDG uptake [16] . Thus, we expected that 18 F-FGD PET could provide anatomical reference and reflect the metabolism of the infarcted area. To facilitate image coregistration, the animals were kept at exactly the same position on the scanning gantry during the tracer injection and the imaging process. Representative myocardial short-axis serial slices from the same animal following in vivo PET imaging of 18 F-AlF-NOTA-PRGD2 and 18 F-FDG are presented in Fig. 3 . A high level of 18 F-FDG accumulation was visualized homogeneously in normal heart while almost no 18 F-AlF-NOTA-PRGD2 uptake was observed in the heart region. Compared with that in sham-operated rats, the heart in MI/R rats still showed decreased 18 F-FDG uptake in the anterolateral wall of the left ventricle at day 7 after surgery. At the same time, localized 18 F-AlF-NOTA-PRGD2 uptake was observed in rats after MI/R. Moreover, the localization matched perfectly with the areas of infarcted myocardium, as evidenced by the decrease of 18 F-FDG uptake. To evaluate angiogenesis after MI/R, longitudinal PET imaging was performed at 3 days, 1 week, 3 weeks, and 4 months after surgery using 18 imaging probe. Figure 4a shows representative transaxial PET images with 18 F-AlF-NOTA-PRGD2. Compared with the control group, uptake increase was observed as early as day 3 after MI/R and reached the maximum between 1 and 3 weeks after MI/R. The signal then decreased after 4 months. Animals from both groups showed increased uptake of 18 F-AlF-NOTA-PRGD2 at the region of the surgical wound, reflecting an angiogenic response during the wound healing process.
The quantitative results based on PET imaging are presented in Fig. 4b . The myocardial uptake of 18 F-AlF-NOTA-PRGD2 in the sham group at 1 week after surgery was determined to be 0.15±0.04%ID/g. MI/R induction was associated with a significant increase in uptake of 18 F-AlF-NOTA-PRGD2 in the anterolateral wall of the myocardium after 3 days reperfusion (0.28±0.03%ID/g, p<0.05).
18 F-AlF-NOTA-PRGD2 localization in the MI/R was maximal between 1 and 3 weeks (0.59±0.16 and 0.55±0.13%ID/g, respectively, p<0.01). Uptake of the radiotracer decreased by 4 months, but localization of the radiotracer was still greater than that in the sham group (0.31±0.01%ID/g, p<0.05).
In order to further confirm integrin receptor binding specificity of 18 F-AlF-NOTA-PRGD2, we used non-radiolabeled integrin-specific ligand, E[c(RGDyK)] 2 , as a blocking agent. Both imaging and quantification demonstrated that tracer uptake in the infarcted myocardium could be blocked by excess amount of unlabeled RGD peptide. The tracer uptake was significantly lower than that in the unblocked rats at 1 week after MI/R (0.22±0.08 vs 0.59±0.16%ID/g, p<0.05). We also labeled a RAD peptide with a similar procedure and found that the localized tracer uptake was 0.21±0.01%ID/g at 1 week after MI/R, which is significantly lower than that of 18 F-AlF-NOTA-PRGD2 (p<0.01). These results further substantiated the specificity of integrin-targeting imaging.
Ex vivo autoradiography
In parallel with in vivo PET imaging, we also performed ex vivo autoradiography to validate the quantitative results based on PET images. Typical autoradiographic images and averaged uptake ratios at different time points are shown in Fig. 5 . At 3 days, 1 week, and 3 weeks after MI/ R, increased signal intensity was clearly shown in the infarcted and ischemic area, evidenced by TTC stains and H&E staining. The results confirmed the localized high level of 18 F-AlF-NOTA-PRGD2 uptake as presented by noninvasive PET imaging. Quantification data demonstrated that the trend of the uptake ratio of 18 F-AlF-NOTA-PRGD2 reached maximum at 1 and 3 weeks after MI/R, which is consistent with PET imaging results. Once blocked with excess amount of unlabeled RGD peptide, the decreased uptake of 18 F-AlF-NOTA-PRGD2 was also reflected on the autoradiographic images. A much lower signal intensity was also observed with the control tracer 18 F-AlF-NOTA-RAD (p<0.05).
CD31 and integrin immunostaining
To further investigate the mechanism of increased 18 F-AlF-NOTA-PRGD2 uptake after MI/R, we performed CD31 and CD61 immunostaining to follow the changes of microvasculature and integrin β 3 expression at different time points after the surgery. As shown in Fig. 6 , in the normal heart from the sham group, positive CD31 staining was distributed homogeneously among myocardium, representing an orderly architecture of the microvasculature. At the same time, a very low level of CD61 signal was observed. At 3 days after MI/R, the pattern of the CD31 signal was different from that in the normal myocardium. An increased F-AlF-NOTA-PRGD2 uptake region from the infarcted/ischemic myocardium is indicated by white arrows, and the triangle indicates the 18 F-AlF-NOTA-PRGD2 signal from the surgical wound, which is present in both sham-operated and MI/R animals. b Quantification of 18 F-AlF-NOTA-PRGD2 uptake after MI/R over time, expressed in %ID/g of tissue.
18 F-AlF-NOTA-PRGD2 uptake was highest at 1 week postoperatively compared with the sham group. *p<0.05; **p<0.01 CD61 signal was observed along with a CD31-positive region but without apparent colocalization. At 1 week after MI/R, stronger and more diffusive CD31 and CD61 signals were recognized with dominant colocalization. The similar pattern was also observed in the infarcted/ischemic myocardium at 3 weeks after MI/R. After 4 months, the vascular density was dramatically lower than that in the normal myocardium, indicated by the sparse CD31-positive region. The CD61 signal still remained, but with a considerably lower level as compared with that at 1 or 3 weeks after MI/R.
Discussion
In a mouse MI model, it has been found that the maximum quantitative uptake in the infarct area was highest at 2 weeks after MI with SPECT imaging [28] . With 18 F-Galacto-RGD as the PET tracer, Higuchi et al. also demonstrated that focal accumulation in the infarct area started at day 3 and peaked between 1 and 3 weeks after reperfusion [14] . In this study we applied for first time a one-step labeled PET tracer 18 FAlF-NOTA-PRGD2 to visualize and quantify the temporal changes of integrin α v β 3 expression during ischemiainduced angiogenesis in a rat MI/R model. Increased focal tracer retention was observed as early as 3 days after onset of ischemia and the tracer accumulation peaked at 1 and 3 weeks in the infarcted and peri-infarct zones. At 4 months after MI/R, 18 F-AlF-NOTA-PRGD2 uptake within the myocardium decreased from the peak level but was still higher than that in the remote myocardium. Thus, the imaging results with 18 F-AlF-NOTA-PRGD2 PET revealed a similar pattern of tracer uptake in the infarct area.
Extracellular matrix (ECM) proteins such as vitronectin, fibrinogen, and fibronectin interact with integrin via the RGD sequence. Due to its high affinity and selectivity for the receptor, the pentapeptide cyclo(RGDfK) became the most prominent structure for the development of molecular imaging compounds to evaluate integrin α v β 3 expression [29] . Compared with RGD monomer including Galacto-RGD, the dimeric RGD peptide tracers showed higher tumor integrinspecific accumulation and more favorable in vivo kinetics [30] . The use of multimeric cyclic RGD peptides to improve the integrin α v β 3 binding affinity was based on the fact that the interaction between integrin α v β 3 and RGD-containing ECM proteins involves multivalent binding sites with clustering of integrins [31] . With the dimeric RGD peptide tracer 18 F-AlF-NOTA-PRGD2, significant focal myocardial uptake was observed on PET images (Fig. 4) . Quantitative data showed that the tracer uptake reached a high level plateau at 1 and 3 weeks after MI/R with 0.59±0.16 and 0.55±0.13%ID/g, respectively, which is significantly higher than those reported using the monomeric RGD tracer 18 F-Galacto-RGD (less than 0.3%ID/g) [14] .
The dimeric RGD peptide tracer 18 F-FPPRGD2 we developed previously [30] has been approved by the US Food and Drug Administration (FDA) through an exploratory investigative new drug (eIND) mechanism (IND 104150). The initial pilot studies in humans demonstrated that the administration of 18 F-FPPRGD2 was well tolerated, with no marked effects on vital signs, ECG readings, or laboratory values [32] . Synthesis of 18 F-FPPRGD2 usually requires two HPLC purifications, which is time-consuming and consequently results in low labeling yield. Alternatively, a onestep route for labeling has been investigated by several groups including us [17, 23, 24] . By taking advantage of the reaction of the 18 F-fluoride-aluminum complex to a preattached chelator on RGD peptides, a novel dimeric RGD peptide tracer, 18 F-AlF-NOTA-PRGD2, has been prepared without the need of HPLC purification and still maintaining reasonable specific activity level [24] . Also it has been demonstrated that modification of RGD peptides with NOTA did not significantly change the biological binding affinities [23] . In this study, the labeling efficiency for 18 FAlF-NOTA-PRGD2 was consistently between 20 and 25%. The total synthesis time was about 25 min without HPLC purification. The radiochemical purity was over 97%. It is reasonable to surmise that the simplicity of the labeling process of 18 F-AlF-NOTA-PRGD2 would be very attractive for clinical translation, especially when applied to patients with cardiovascular diseases.
Increased 18 F-AlF-NOTA-PRGD2 uptake in the periinfarct and infarcted zones was associated with increased integrin α v β 3 expression induced by angiogenesis and tissue remodeling after MI/R. As confirmed by anti-CD61 staining, normal myocardium showed minimal integrin β 3 expression. In contrast, increased integrin β 3 expression was observed as early as 3 days after MI/R and kept increasing to a peak level between 1 and 3 weeks after MI/R (Fig. 6) . In a canine model of MI/R, Frangogiannis et al. [33] found that capillary density peaked at week 3. We also identified the changes of morphology and density of microvasculature after MI/R based on anti-CD31 staining. It is worth noting that the signals from CD31 and CD61 were not always colocalized. One possible explanation is that inflammation occurred after MI/R since infiltrated macrophages do express high levels of α v β 3 integrin [34] . Indeed, H&E staining at 1 week after infarction (Fig. 5a ) suggested inflammatory cell infiltration among affected myocardium. We also cannot exclude the possibility of proliferating myofibroblasts taking up RGD peptide tracer in the infarcted and peri-infarct area, as reported previously [28, 35] . As shown in Fig. 5a , significant Fig. 6 Immunofluorescence staining of CD31 and CD61 (integrin β 3 ) in sham-operated and MI/R animals over time wall thinning was observed at 4 months after MI/R, indicating the formation of myocardial scar. Consequently, how to delineate angiogenesis and tissue remodeling after MI/R by 18 F-AlF-NOTA-PRGD2 PET imaging will still need further investigation.
FDG PET imaging was used to provide an anatomical reference for 18 F-AlF-NOTA-PRGD2 PET images, because the latter approach lacks detailed anatomical information. Normal myocardium showed very high FDG uptake due to the high glucose metabolism. At 1 week after MI/R, the ischemic myocardium showed decreased FGD uptake, which may probably be due to lower viability caused by MI/R. However, at 2 weeks after MI/R, FDG PET imaging showed increased uptake in the infarct area. The exact reason needs further investigation, but we speculated that it might be related to remodeling and inflammation induced by MI/R.
In summary, longitudinal PET imaging using 18 F-AlF-NOTA-PRGD2 provided temporal information of integrin α v β 3 changes after MI/R in a noninvasive and quantitative mode. Moreover, the localization and quantification of PET imaging was further validated by ex vivo autoradiography, in vivo FDG PET imaging, and corresponding H&E and TTC staining. However, one inherent limitation of PET imaging is that the spatial resolution was not high enough to define exactly the subarea of myocardial infarction and its border zone.
Conclusion
PET imaging using a one-step labeled tracer, 18 F-AlF-NOTA-PRGD2, allows noninvasive visualization of ischemia/reperfusion-induced myocardial angiogenesis longitudinally. The favorable in vivo performance and easy production method of this integrin-targeted PET tracer facilitates its future clinical translation for lesion evaluation and therapy response monitoring in patients with occlusive cardiovascular diseases and pro-angiogenic drug screening in the preclinical setting.
